Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review

2017 ◽  
Vol 10 (7) ◽  
pp. 753-762 ◽  
Author(s):  
Jesús Honorato Pérez
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

scholarly journals Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

2015 ◽  
Vol 58 (18) ◽  
pp. 7128-7137 ◽  
Author(s):  
Tetsuo Asaki ◽  
Keiichi Kuwano ◽  
Keith Morrison ◽  
John Gatfield ◽  
Taisuke Hamamoto ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

scholarly journals Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report

2021 ◽  
Vol 20 (5) ◽  
pp. 3010
Author(s):  
E. A. Rezukhina ◽  
O. V. Rodnenkov ◽  
T. V. Martynyuk
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
High Risk ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
World Health ◽  
Class Iii ◽  
National Medical ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease in effort tolerance. According to a comprehensive examination, single factors of high risk and unfavorable prognosis were identified. Due to systemic hypotension when using inhaled iloprost, selexipag was added to therapy. According to control hospitalization, 8-month selexipag therapy improved the patient's condition, as well as high risk factors were not revealed. Selexipag is a selective oral prostacyclin receptor agonist recommended for longterm IPAH therapy in adult patients.

scholarly journals Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

2012 ◽  
Vol 40 (4) ◽  
pp. 874-880 ◽  
Author(s):  
Gérald Simonneau ◽  
Adam Torbicki ◽  
Marius M. Hoeper ◽  
Marion Delcroix ◽  
Kristóf Karlócai ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Prostacyclin Receptor ◽  
Pulmonary Arterial

scholarly journals Hemodynamic Effects of the Oral Prostacyclin (IP) Receptor Agonist Ralinepag in Pulmonary Arterial Hypertension

CHEST Journal ◽  
2017 ◽  
Vol 152 (4) ◽  
pp. A738
Author(s):  
Fernando Torres ◽  
Harrison Farber ◽  
Arsen Ristić ◽  
Vallerie McLaughlin ◽  
John Adams ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Hemodynamic Effects ◽  
Ip Receptor ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document